Navigation Links
Allos Therapeutics' PDX Granted Orphan Medicinal Product,Designation by the European Commission

t. The primary endpoint of the study is objective response rate (complete and partial response). Secondary endpoints include duration of response, progression-free survival and overall survival. In August 2006, the Company announced that it reached agreement with the FDA under the Special Protocol Assessment process on the design of this pivotal Phase 2 trial. The Company currently anticipates that patient enrollment at approximately 35 centers in the U.S., Canada and Europe will be completed by the third quarter of 2008.

About PDX (pralatrexate)

PDX is a novel, small molecule chemotherapeutic agent that inhibits dihydrofolate reductase, or DHFR, a folic acid (folate)-dependent enzyme involved in the building of nucleic acid, or DNA, and other processes. PDX was rationally designed for efficient transport into tumor cells via the reduced folate carrier, or RFC-1, and effective intracellular drug retention. We believe these biochemical features, together with preclinical and clinical data in a variety of tumors, suggest that PDX may have a favorable potency and toxicity profile relative to methotrexate and certain other DHFR inhibitors.

About Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas, or PTCLs, are a biologically diverse group of blood cancers that account for approximately 10% to 15% of all cases of non-Hodgkin's lymphoma (NHL), or about 6,700 patients. The average five year survival rate for PTCL patients is approximately 25%. There are currently no pharmaceutical agents approved for the treatment of either first-line or relapsed or refractory PTCLs.

About Allos Therapeutics, Inc.

Allos Therapeutics, Inc. (ALTH) is a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer. The Company has two product candidates in late-stage clinical development: EFAPROXYN (efaproxiral), a radiation sensitizer currently under evaluation in a pivotal P
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
4. Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
5. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
6. DUSA Pharmaceuticals Receives Orphan Drug Desi gnation for Levulan PDT to Treat Esophage al Dysplasia
7. AOP Orphan Pharmaceuticals and Lantibio Announce Positive Phase II Study with Novel Cystic Fibrosis Therapy
8. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
9. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
10. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
11. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
Post Your Comments:
(Date:8/20/2014)... 20, 2014 Torrance Memorial Medical Center ... ventilator technology from Covidien to provide a simple, ... The acute care ventilator is designed ... conventional mechanical ventilation, and help clinicians move patients ... on mechanical ventilation are often sedated to ease ...
(Date:8/20/2014)... 20, 2014 Children aren,t the only ... to help prevent disease. The Centers for Disease ... adults, but currently, many adults are not following ... Immunization Awareness Month, and the American Lung Association ... those with lung disease, to talk with their ...
(Date:8/20/2014)... 20, 2014 Research and Markets  has announced ... report to their offering. Global Market ... on Pralmorelin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
Breaking Medicine Technology:Torrance Memorial Medical Center Acquires Advanced Ventilator Technology to Enhance Patient Care 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Global Market Report of Pralmorelin 2
... for Safe Biologic Medicines will have an open ... on biologic medicines and pharmacovigilance.  Dr. Richard Dolinar, a practicing ... newly released FDA draft guidances for manufacturers of ... it and why is it important?  will ...
... MusculoskeletalNetwork , an online resource for ... now features a summary of the key orthopedic findings ... Academy of Orthopaedic Surgeons ( AAOS ) this February ... offers orthopedists a comprehensive program with the latest in ...
Cached Medicine Technology:Alliance for Safe Biologic Medicines Announces New Webinar on February 16 2UBM Medica's Musculoskeletal Network Highlights Key Orthopedic Findings From AAOS 2UBM Medica's Musculoskeletal Network Highlights Key Orthopedic Findings From AAOS 3
(Date:8/20/2014)... The Board of Directors of top international ... pleased to announce the expansion of its healthcare ... and the surrounding region. In support of this strategic ... has relocated to the firm’s office in Shanghai, China, ... design and to better support regional clients. , ...
(Date:8/20/2014)... persistent and deadliest infectious diseases in the world, killing ... who study tuberculosis have long debated its origins. New ... Africa to seals and sea lions that brought the ... people there before Europeans landed on the continent. , ... Source of New World Human Tuberculosis," was published in ...
(Date:8/20/2014)... to spawning grounds through fast-moving waters may be at ... scientists. , When salmon encounter turbulent, fast-moving water ... they must move upstream using a behaviour known as ... , "Days after sockeye passed through extremely fast-moving water, ... distance from their spawning grounds," said Nicholas Burnett, a ...
(Date:8/20/2014)... New York (PRWEB) August 20, 2014 ... the use of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) ... notes that two U.S. Senators from New York are ... seek a recall of the devices. In a letter ... both Democrats, also implored the agency to seriously consider ...
(Date:8/20/2014)... NEW YORK, NY (August 20, 2014) Research from ... a critical role in stomach cancer growth and that ... be an effective treatment for the disease. The study ... MD, in collaboration with Duan Chen, MD, PhD, in ... Science Translational Medicine . , "Scientists have long observed ...
Breaking Medicine News(10 mins):Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:Salmon forced to 'sprint' less likely to survive migration 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes Senators’ Letter Seeking FDA Morcellator Recall 4Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... Conn.Yale School of Medicine is hosting a two-day symposium Nov. ... the late actor John Ritter, who died of an aortic ... Diseases: Lux et Veritas will be held in Mary S. ... program is John Elefteriades, M.D., section chief of cardiothoracic surgery ...
... the United States via Haiti, probably arriving in just one ... new research. , After the virus, HIV-1, entered the ... results show that the strain of virus that spawned the ... is earlier than a lot of people had imagined," said ...
... and Asia are born and die without leaving a ... little information on which to base public health decisions, ... and colleagues say in a paper published today (Oct. ... , However, affordable solutions exist to collect these vital ...
... study finds it can prevent or shorten the illness , ... in the blood may help prevent pneumonia in elderly nursing ... at Tufts University looked at 617 people 65 and older ... found that those with normal blood zinc concentrations were about ...
... National Campaign to Inspire and ... Educate that Prevention is Possible, BERKELEY, Calif., Oct. 29 ... lifetime. Although 50 percent,of women think breast cancer is hereditary, only ... disease. LUNA, the makers of whole nutrition bars for women(R), ...
... patients with Philadelphia, chromosome-positive chronic myeloid leukemia resistant or intolerant to ... ... Novartis can offer physicians and patients a ... Tasigna(R),(nilotinib) capsules have been approved in the US as a new ...
Cached Medicine News:Health News:HIV's path out of Africa: Haiti, the US then the world 2Health News:HIV's path out of Africa: Haiti, the US then the world 3Health News:Scandal of invisibility plagues countries with no civil registries 2Health News:Scandal of invisibility plagues countries with no civil registries 3Health News:Zinc Helps Elderly Ward Off Pneumonia 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 2Health News:LUNA Pure Prevention Survey Confirms Breast Cancer Misconceptions 3Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 2Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 3Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 4Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 5Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 6Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 7Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 8Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 9Health News:Video and Photo: Tasigna(R) Receives US Approval Providing New Hope to Chronic Myeloid Leukemia Patients With Resistance or Intolerance to Existing Therapies 10
... Endoscopic CycloPhotocoagulation (ECP) is a surgical ... endoscopy and visualized laser application. The ciliary ... by the surgeon, from the anterior or ... time. The target tissues are easily and ...
... German Craftsmanship have produced the ... world. Ocutek® now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek® ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
... German Craftsmanship have produced the ... world. Ocutek® now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
Medicine Products: